Not exact matches
Ocrelizumab was heralded as a
breakthrough, and in March, the U.S. Food and
Drug Administration approved it as a treatment for primary progressive and relapsing - remitting MS. Genentech now sells the drug as Ocre
Drug Administration
approved it as a treatment for primary progressive and relapsing - remitting MS. Genentech now sells the
drug as Ocre
drug as Ocrevus.
Nonetheless, an FDA press release described Zykadia as «a
breakthrough therapy
drug approved four months ahead of review completion goal date,» a message that was reflected in reporting by the Washington Post.
Taking that concept into biomedical research has yielded a
breakthrough: This past May the mTOR inhibitor everolimus was
approved by the U.S. Food and
Drug Administration for the treatment of advanced pNET, the first drug in this class approved for this dise
Drug Administration for the treatment of advanced pNET, the first
drug in this class approved for this dise
drug in this class
approved for this disease.